Compare DDI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDI | PRTC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.6M | 464.3M |
| IPO Year | 2020 | N/A |
| Metric | DDI | PRTC |
|---|---|---|
| Price | $8.95 | $16.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 57.3K | 4.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | ★ $4.31 | $8.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.09 | $13.30 |
| 52 Week High | $11.25 | $20.00 |
| Indicator | DDI | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.51 | 41.11 |
| Support Level | $8.64 | $15.72 |
| Resistance Level | $9.32 | $18.10 |
| Average True Range (ATR) | 0.35 | 0.50 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 40.22 | 8.09 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.